Share Name Share Symbol Market Type Share ISIN Share Description
Venture Life Group Plc LSE:VLG London Ordinary Share GB00BFPM8908 ORD 0.3P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 29.00 10,000 08:00:00
Bid Price Offer Price High Price Low Price Open Price
28.00 30.00 29.00 29.00 29.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 18.77 0.71 0.42 69.0 24
Last Trade Time Trade Type Trade Size Trade Price Currency
08:03:41 O 10,000 28.30 GBX

Venture Life (VLG) Latest News

More Venture Life News
Venture Life Takeover Rumours

Venture Life (VLG) Discussions and Chat

Venture Life Forums and Chat

Date Time Title Posts
06/12/201910:40ValueGrowth Investing29,490
21/11/201909:42Venture Life Group plc185
02/4/201509:58Venture Life Group - Intro video-

Add a New Thread

Venture Life (VLG) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
08:03:4628.3010,0002,830.00O
2019-12-05 16:14:1329.3068,14419,966.19O
2019-12-05 15:09:1729.5030,0008,850.00O
2019-12-05 14:54:1329.505,0501,489.75O
2019-12-05 11:20:2829.306,0001,758.00O
View all Venture Life trades in real-time

Venture Life (VLG) Top Chat Posts

DateSubject
06/12/2019
08:20
Venture Life Daily Update: Venture Life Group Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker VLG. The last closing price for Venture Life was 29p.
Venture Life Group Plc has a 4 week average price of 28.50p and a 12 week average price of 28.50p.
The 1 year high share price is 54p while the 1 year low share price is currently 28.50p.
There are currently 83,712,106 shares in issue and the average daily traded volume is 110,668 shares. The market capitalisation of Venture Life Group Plc is £24,276,510.74.
01/12/2019
22:09
thelongandtheshortandthetall: I wondered if trak was able to survive coz qtx are pulling out. Enabling trak to charge a bit more etc. Haven't really looked at trak but that could be the reason for their recent share price rise. I thought I read somewhere that they were going to release an update on the 4th of dec but cant I find it now.. It may have been about 4th dec 18 :( From the recent interims: Andy Walters, Chief Executive Officer of Quartix, commented: "We are delighted with the expansion of our fleet subscription base in the First Half, which resulted from an increased level of investment in customer acquisition. New fleet installations grew by 48% compared with the same period last year... -- This 48% increase should really benefit the next update (dec/jan) as from what I can tell is they offer 3 months free, so big load of the new fleet installs revenue wouldn't be in the interims but will be in the next quarter. Hope that makes sense - I am only guessing and trying to learn btw. But it does make me feel comfortable about the future, near and mid term. They may still have some insurance work booked in the update but it looks like it wont be long till profits for fleet alone outstrips the old fleet and insurance combo. IE return QTX to growth and growing the better side of the business too. The fleet uptake looks like it has been 'roughly' replacing insurance decline. Back to growth soon hopefully and then the share price can get back on track. To me QTX has simply been in the doldrums for a couple of years but I think market will sniff a new wind in the air. I think they should hold the divi where it is and go for growth big time. Agree. reducing the need for specialist installation is a bonus. cost savings there. Hopefully the software and service can create the moat as apposed to difficulty of physically changing components and hassle to customer. Also this from the interims: Subscription base grew by 12% to 138,081 vehicles (31(st) December 2018: 123,157) -- So if we extrapolate that out for the year to 24% subscription base growth, how much of that falls to the bottom line? 24% would be good but as a subscription business like this benefits hugely from economises of scale it could mean upto 40% profit increase.. on the extra 24% subscriptions. Tired out and guessing this evening by the way. But a (long way off) doubling of 'quality' subscription based revenue could mean a tripling of profit.
01/12/2019
10:39
redartbmud: Breedon Yes, it has proved to be a massive BFTD. It is a case study in strategy and tactics. The scenario was one where: 1. A major shareholder, closely aligned to another major shareholder had sold the entire stake, without any real explanation for the reasons behind the deal. 2. One of the founders, who had been chairman, has previously sold 50% of a large shareholding, on retirement. 3. There has been an overhang of shares in the market. 4. There are regular large size trades taking place. 6. The PE is relatively modest, but the share price isn't underpinned by by a dividend. I hold a sizeable stake, relative to the size of my portfolio, and the type of share it is. It was quite obvious that the there was a galaring disconnect, in the share price, based on "underlying" fundamentals. The probability of the correction was better than average. The timing of the correction was opaque, given macro market conditions, exacerbated by the two large divestments, although there is an expectation that the recipients of those shares might be expected to hold for the near term. The counter argument being the lack of dividend, hence the need to regularly take capital gains, in lieu of dividends, to create income. Holding a larger number of shares extends the percentage of those non-income generating assets, taking away that opportunity in alternative investments. If the share price recovers quickly then it is a successful trade. If it languishes, in thr depths for months, it is a failure. I am not sure that charting thr share is the answer to a specific set of circumstances. No right answer. red
25/11/2019
09:21
apad: Been musing on FEVR. Before this rns the UK had topped out and the US was the ambition (with lots of news about the US structure, hiring and distribution). The share price dropped heavily (I bought four times in Nov). So, out comes the rns - the UK is still topped out and the US has increased, but not to any great extent. The share price rises significantly. It seems that investors exemplify the quote: "The more we attempt to predict the future, the more we describe the present." apad
22/11/2019
08:29
redartbmud: tlatsatt Worth looking at the chart, with the comparison to the FTSE100. Currently the share price has [erformed very well, but historically it has been a train wreck. Maybe better times are on the horizon, at last! From what I have seen of share price movements: the only significant moves have been downwards, on the back of negative news, both or markets and company specific. They have been the subject of very negative press comment. Apart from huge structural business problems, identified by the tintins, the popular press have slaughtered them for their performance, charges, service etc. etc. It is very unusual for the share price volatility to be sufficient to justify a short term trade. Just a few thoughts. red
08/11/2019
09:32
redartbmud: Bree When you look at the trades, chunks of 750k to 100k, at a time, are not unusual. That is a reasonably big wedge for a PI. I am waiting to see where the M1 shareholding has landed. The swapping of such big numbers, of shares, in recent days, has been unsettling. Continual adverse comment on the construction sector is a big negative driver, on the share price. When Lab. or Con. get into government, we are supposed to see a big stimulus in the sector. As a company reliant on volumes, that should send the share price north again. I might pare back my holding, if it returns to the 70p level, especially as it is unlikely to pay a dividend. red
29/10/2019
09:00
redartbmud: bamboo Yes please. As a Rsw watcher, for many a year, I have to support APAD in his comments. I have tried hard to 'read' the trends and to try to forward 'guess', or predict the next move, especially around announcement times. The share price moves have often been perverse. I have also tried to think of the factors that may influence such moves. The controlling holding is in the hands of the founders, McMurtry and Deer, with 52%. Much of the rest are tightly held, although that fact may now be changing. Share price moves do tend to be seriously over-exaggerated, hence my interest in the opportunities, that periodically present themselves, to take advantage of such temporary aberrations. red
28/10/2019
19:15
thelongandtheshortandthetall: APAD All is well then 😃 Not sure about SOS for tomorrow. Not sure how many shares were traded today but it made the share price rise 25% and an equal amount of action tomorrow could do the reverse I guess. I hope todays RNS will support the share price till the interims. Not that we can expect too much more info. But they might able to elucidate further on marketing responses up to 27th November. Unless someone or institution is building a position the share price will probably drift for the next few days as the traders move onto pastures new.
25/10/2019
17:33
lomax99: GCI on BVXP today, written when share price was 3400: This member of the GCI portfolio is up 60% since we tipped it in March last year. Results for the year to June were as expected and the shares are unsurprisingly consolidating given a p/e in the high 20s. Revenue growth was 16% on a like-for-like basis with eps up 15%. This is a good performance from a high quality business but does not maintain a record of positive surprises and upgrades which drove the solid uptrend in the shares to the peak of £40 in May. The main driver continues to be antibodies for vitamin D deficiency testing where sales grew 27%. Management say that this product continues to surpass expectations. While there is evidence of sales values starting to plateau in the US and Europe with lower prices offsetting growth in volumes, newer markets in Asia should continue to move sales forward. The next leg of growth rests on the success of the high- sensitivity troponin test for heart attack. The first revenues of £120,000 were booked during the period with the test in its early stages of being rolled-out by Siemens and management “...has no reason to question our belief that these assays will generate significant value into the future”. There is another special dividend which puts the shares on a 3.5% yield. Happy to buy on weakness. Further comment on their portfolio: Our main detractor over the month was Bioventix which cost us 1.2%. As discussed in the Digest, the results were fine but not enough to trigger upgrades and with a p/e in the high 20s there has been an understandable bout of profit taking. We did some of that ourselves back in February at the 3,485p level but are happy holding on to what remains a very high quality, cash generative, growth stock. The special dividend means the shares are about to go ex a 90p payout which is a near 3% yield on the current share price of 3160p. At that level the shares are on a current year p/e of 25x to June 2020, falling to 23x the following year. This is close to buying territory; so I am happy to hold firmly onto our position.
10/8/2019
13:41
apad: Scott on BUR " reviewed Burford's rebuttal document here in yesterday's SCVR. It comes across very well, I think - giving plausible-sounding explanations to refute Muddy Water's claims. Similarly, I tuned in to the conference call yesterday afternoon, but had enough after about 90 minutes. Again, management seemed thorough in their answers, and give the impression of being determined to restore theirs and the company's reputation. Subjectively, it seemed to me that management were giving honest answers, and didn't seem to be hiding anything. It seems fairly clear that Burford is likely to take Muddy Waters to court, over what it seems as market manipulation. I think that's probably a good thing. Shorting dossiers are fine if they reveal a fraud, like the many Chinese companies, and others like Globo, and Quindell. However, if they try to deliberately trigger a plunge in share price, by putting out a dossier that turns out to be full of inaccuracies & misrepresentations, then the shorter looks, prima facie, guilty of market manipulation. All that remains now is how to value BUR? Given that current huge profits are probably not sustainable, due to the big cases eventually settling, then a PER basis is problematic. I would suggest valuing it on a multiple of NAV. At 850p per share right now, the market cap is £1.86bn. Its last reported NTAV was $1,420m (which I've calculated as $1,567m NAV, less $134m goodwill and $13m intangibles). That works out as at NTAV of £1,176m when coverted into sterling at £1=$1.207. Therefore, at 850p the share price is at a 58% premium to NTAV. That seems a bit steep if anything, to my mind, given that the company forward books a lot of the profits on cases in progress. Therefore, on valuation grounds, I'm not interested in buying any shares here. One of the questioners on the conference call yesterday made the interesting point that even experts find this company difficult to understand. So is it a suitable investment for private investors (shares or bonds)? Probably not, especially after the extreme volatility we've seen this week. Opinions differ on how to see the concentration of profits into the top 4 cases. A bull would say that the company showed how canny it was in identifying these lucrative cases, deserving a premium share price. A sceptic might point out that once the big cases end, then there's no guarantee the company will be able to replace them, hence profits would fall because margins on smaller cases are lower. What an interesting situation! I really don't have a strong opinion either way. A key point to research, is what are the terms of the borrowing facilities Burford uses? Management said they have something like $400m in cash on hand, if I heard that correctly on the conference call. So it sounds as if there are no cash problems. However, that could change if debt facilities were withdrawn. Therefore, bulls on this stock would need to (and some probably already have) checked what the terms of the debt are. If the debt is secure, then there's no problem."
12/4/2019
14:05
redartbmud: Beddard on 16 Sept 2016. LTIP: Crudely, the incentive could award Goodwin directors options on 1% of the company's share capital in less than three years' time if the share price reaches £35 (today it is around £20). The options would cost them a minimal amount to exercise and each director's award would be worth around £2.5 million*. The cost to shareholders would be an 8% dilution in their holdings. A small price to pay, perhaps, considering the share price would have risen about 70%. Currently 7.2m shares in issue, so 1% = 720,000 shares. Any bets, the current share price is £31.60 up £1 today? red
Venture Life share price data is direct from the London Stock Exchange
Your Recent History
LSE
VLG
Venture Li..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191206 10:45:08